模拟目标试验比较来曲唑与枸橼酸氯米芬诱导排卵的有效性
该研究模拟目标试验,利用美国大型医疗索赔数据库2011-2015年数据,比较来曲唑与枸橼酸氯米芬连续六个周期诱导排卵的妊娠结局。在多囊卵巢综合征(PCOS)女性中,来曲唑的妊娠、活产、多胎妊娠、早产、新生儿重症监护室(NICU)入住和先天畸形的风险均高于氯米芬;而在不明原因不孕女性中未观察到治疗差异。
要点
- PCOS女性中来曲唑的妊娠概率为43%,氯米芬为37%(风险差RD=6.0%;95%CI:4.4,7.7)。
- PCOS女性中来曲唑的活产概率为32%,氯米芬为29%(RD=3.1%;95%CI:1.5,4.8)。
- 不明原因不孕女性中,两种治疗的妊娠和活产概率相似。
核心结论
- 在不明原因不孕女性中,来曲唑与氯米芬的活产概率相当。
- 在PCOS女性中,来曲唑在实现活产方面似乎略更有效。
- 在不明原因不孕女性中,两种治疗的新生儿结局相似;未证实氯米芬相比来曲唑有更高的不良新生儿结局风险。
- 在PCOS女性中,来曲唑治疗的不良新生儿结局风险略高于氯米芬,这些效应可能部分通过来曲唑组多胎妊娠风险增加所介导。
研究设计与样本
- 模拟目标试验,比较来曲唑与枸橼酸氯米芬诱导排卵的有效性,并按PCOS和不明原因不孕状态分层。
- 使用美国大型医疗索赔数据库2011-2015年的真实世界数据。
- 分析18120名启动来曲唑的女性和49647名启动氯米芬的女性,年龄18-45岁,无糖尿病、甲状腺疾病、肝病或乳腺癌病史,且试验启动前3个月内未接受生育治疗。
- 治疗策略为连续六个周期使用枸橼酸氯米芬或来曲唑。
主要发现
- 在PCOS女性中,意向性治疗分析下来曲唑的妊娠概率为43%,氯米芬为37%(RD=6.0%;95%CI:4.4,7.7)。
- 在PCOS女性中,意向性治疗分析下来曲唑的活产概率为32%,氯米芬为29%(RD=3.1%;95%CI:1.5,4.8)。
- 在PCOS女性中,符合方案分析下多胎妊娠风险来曲唑为19%,氯米芬为9%。
- 在PCOS女性中,符合方案分析下早产风险来曲唑为20%,氯米芬为15%;小于胎龄儿(SGA)风险来曲唑为5%,氯米芬为3%。
- 在PCOS女性中,符合方案分析下NICU入住风险来曲唑为22%,氯米芬为16%;活产者中先天畸形风险来曲唑为8%,氯米芬为2%。
关键数值与推荐
- 在PCOS女性中,意向性治疗分析下来曲唑妊娠概率43% vs 氯米芬37%(RD=6.0%;95%CI:4.4,7.7)。
- 在PCOS女性中,意向性治疗分析下来曲唑活产概率32% vs 氯米芬29%(RD=3.1%;95%CI:1.5,4.8)。
- 在PCOS女性中,符合方案分析下多胎妊娠风险来曲唑19% vs 氯米芬9%。
- 在PCOS女性中,符合方案分析下早产风险来曲唑20% vs 氯米芬15%;SGA风险来曲唑5% vs 氯米芬3%。
- 在PCOS女性中,符合方案分析下NICU入住风险来曲唑22% vs 氯米芬16%;活产者中先天畸形风险来曲唑8% vs 氯米芬2%。
临床怎么用
- 对于不明原因不孕女性,来曲唑与氯米芬导致的可比活产概率。
- 对于PCOS女性,来曲唑似乎略更有效地实现活产。
- 在不明原因不孕女性中,两种治疗的新生儿结局相似。
- 在PCOS女性中,来曲唑治疗的不良新生儿结局风险略高于氯米芬。
局限性
- 不能完全排除体重指数或不孕 duration 的残余混杂。
- 但调整了行政数据中识别的代理变量后,结果未改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the comparative pregnancy outcomes in women who receive up to six consecutive cycles of ovulation induction with letrozole versus clomiphene citrate? SUMMARY ANSWER: The risks of pregnancy, livebirth, multiple gestation, preterm birth, neonatal intensive care unit (NICU) admission and congenital malformations were higher for letrozole compared with clomiphene in participants with polycystic ovarian syndrome (PCOS), though no treatment differences were observed in those with unexplained infertility. WHAT IS KNOWN ALREADY: Randomized trials have reported higher pregnancy and livebirth rates for letrozole versus clomiphene among individuals with PCOS, but no differences among those with unexplained infertility. None of these trials were designed to study maternal or neonatal complications. STUDY DESIGN, SIZE, DURATION: We emulated a hypothetical trial of the comparative effectiveness of letrozole versus clomiphene citrate for ovulation induction among all women, then stratified by PCOS and unexplained infertility status. We used real-world data from a large healthcare claims database in the USA (2011-2015). PARTICIPANTS/MATERIALS, SETTING, METHODS: We analyzed data from 18 120 women who initiated letrozole and 49 647 women who initiated clomiphene during 2011-2014, and who were aged 18-45 years with no history of diabetes, thyroid disease, liver disease or breast cancer and had no fertility treatments for 3 months before trial initiation. The treatment strategies were clomiphene citrate or letrozole for six consecutive cycles. The outcomes were pregnancy, livebirth, multiple gestation, preterm birth, small for gestational age (SGA), NICU admission and major congenital malformations. We estimated the probability of each outcome under each strategy via pooled logistic regression and used standardization to adjust for confounding and selection bias due to loss to follow-up. MAIN RESULTS AND THE ROLE OF CHANCE: The estimated probabilities of pregnancy, livebirth and neonatal outcomes were similar under each strategy, both overall and among individuals with unexplained infertility. Among women with PCOS, the probability of pregnancy was 43% for letrozole vs 37% for clomiphene (risk difference [RD] = 6.0%; 95% CI: 4.4, 7.7) in the intention-to-treat analyses. The corresponding probability of livebirth was 32% vs 29% (RD = 3.1%; 95% CI: 1.5, 4.8). In per protocol analyses, the risk of multiple gestation was 19% vs 9%, the risk of preterm birth was 20% vs 15%, the risk of SGA was 5% vs 3%, the risk of NICU admission was 22% vs 16% and the risk of congenital malformation was 8% vs 2% among those with a livebirth. LIMITATIONS, REASONS FOR CAUTION: We cannot completely rule out the possibility of residual confounding by body mass index or duration of infertility. However, we adjusted for proxies identified in administrative data and results did not change. WIDER IMPLICATIONS OF THE FINDINGS: Our findings suggest that for women with unexplained infertility, the two treatments result in comparable probabilities of a livebirth. For women with PCOS, letrozole appears slightly more effective for attaining a livebirth. Neonatal outcomes were similar for the two treatments among women with unexplained infertility; we did not confirm the hypothesized higher risk of adverse neonatal outcomes for clomiphene versus letrozole. The risks of adverse neonatal outcomes were slightly greater among women with PCOS who were treated with letrozole versus clomiphene. It is likely that these effects are partially mediated through an increased risk of multiple gestation among women who received letrozole. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Institute of Child Health and Human Development (R01HD088393). Y.-H.C. reports grants from the American Heart Association (834106) and NIH (R01HD097778). P.R. reports grants from the National Institutes of Health. J.H. reports grants from the National Institutes of Health, the Agency for Healthcare Research and Quality, and the California Health Care Foundation during the conduct of the study; and consulting for several health care delivery organizations including Cambridge Health Alliance, Columbia University, University of Southern California, Community Servings, and the Delta Health Alliance. S.H.-D. reports grants from the National Institutes of Health and the US Food and Drug Administration during the conduct of the study; grants to her institution from Takeda outside the submitted work; consulting for UCB (biopharmaceutical company) and Roche; and being an adviser for the Antipsychotics Pregnancy Registry and epidemiologist for the North American Antiepileptics Pregnancy Registry, both at Massachusetts General Hospital. M.A.H. reports grants from the National Institutes of Health and the U.S. Veterans Administration during the conduct of the study; being a consultant for Cytel; and being an adviser for ProPublica. TRIAL REGISTRATION NUMBER: N/A.
引用
- Yland JJ, Chiu YH, Rinaudo P, et al. Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. Hum Reprod. 2022. PMID: 35048945. doi:10.1093/humrep/deac005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。